Filing Flows › Comparisons › CCCC vs SCLX
C4 Therapeutics vs Scilex Holding: CCCC and SCLX compared
C4 Therapeutics is the larger company: $8.5M of revenue in its latest quarter (Q3 2026) against $7.6M for Scilex Holding (Q2 2026). Scilex Holding is growing faster (-23% against -25% a year earlier). C4 Therapeutics is more profitable, with an operating margin of -290.5% against -385.0%.
Where the money goes: CCCC and SCLX
C4 Therapeutics (CCCC) · Q3 2026
C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart follows the revenue to costs, profit and cash.
Scilex Holding (SCLX) · Q2 2026
Scilex Holding, Q2 2026: revenue $7.6M (-23% year over year), operating margin -385.0%, net loss $115M, operating cash flow −$6.7M. The chart follows the revenue to costs, profit and cash.
| C4 Therapeutics (CCCC) | Scilex Holding (SCLX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $8.5M | $7.6M |
| Revenue growth, Y/Y | -25% | -23% |
| Operating margin | -290.5% | -385.0% |
| Net earnings | −$21.8M | −$115M |
| Net margin | -257.9% | — |
| Operating cash flow | −$26.0M | −$6.7M |
Questions
Which is bigger, C4 Therapeutics or Scilex Holding?
C4 Therapeutics is the larger company: $8.5M of revenue in its latest quarter (Q3 2026) against $7.6M for Scilex Holding (Q2 2026).
Is C4 Therapeutics or Scilex Holding growing faster?
Scilex Holding is growing faster (-23% against -25% a year earlier).
Which is more profitable, C4 Therapeutics or Scilex Holding?
C4 Therapeutics is more profitable, with an operating margin of -290.5% against -385.0%.
More: C4 Therapeutics earnings · how C4 Therapeutics makes money · Scilex Holding earnings · how Scilex Holding makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.